icer glp 1 Bank of America: Novo Nordisk and Eli Lilly weight-loss drugs win important victory Incremental cost-effectiveness ratio (ICER) scatterplot

Key Educational Points: Emphasize the experimental nature No clinical trials support this combination Highlight individual compound efficacy Both peptides show strong effects as monotherapies Discuss approved alternatives CagriSema and other studied combinations offer evidence-based options Explain regulatory status Neither compound has FDA approval for metabolic applications as of 2026 Address safety concerns Overlapping side effect profiles create legitimate risks When clients express interest in research peptides, directing them toward compounds with established safety profiles and dosing protocols serves their best interests

These ROS can damage and kill cancer cells

J.MitchellL

For extra punch, Eli Lilly developed a dual agonist called tirzepatide (sold as Zepbound for weight loss), which hits the GLP-1 receptor and a second receptorgastric inhibitory polypeptide (GIP)

However, its role and underlying mechanisms in enhancing edible protein content and reducing fat deposition in fish remain unclear

V., Merzhoeva, Z